Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leramistat in Idiopathic Pulmonary Fibrosis
NCT05951296Phase 2Withdrawn
- Sponsor
- Modern Biosciences
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of Leramistat in idiopathic pulmonary fibrosis (IPF), sponsored by Modern Biosciences. Planned start Aug 2023; status: withdrawn.
02
Drugs
Leramistat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05951296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951296.